Announcements
Monday, 06 February 2012
Clinuvel files European marketing authorisation application for SCENESSE® (afamelanotide)
European regulators to evaluate new drug’s safety and efficacy for ‘orphan’ disease erythropoietic protoporphyria (EPP) Melbourne, Australia and Baar, Switzerland, February 6 2012 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9;…
Tuesday, 31 January 2012
Appendix 4C - quarterly
Rule 4.7B Quarterly report for entities admitted on the basis of commitments Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005. Name of entity CLINUVEL PHARMACEUTICALS LIMITED ABN Quarter ended (“current quarter”) 88…
Monday, 16 January 2012
Appendix 3B
New issue announcement, application for quotation of additional securities and agreement.
Friday, 13 January 2012
Response to Price Query
Response to ASX Price Query letter sent January 12. 2012.
Friday, 30 December 2011
Letter from the CEO
Dear Shareholders, friends, It is a pleasure to report that over the past 12 months Clinuvel has made significant progress in developing SCENESSE® (afamelanotide), a novel product for the treatment…
Tagged under
Tuesday, 20 December 2011
Clinuvel announces positive results from pivotal European Phase III study: endpoints demonstrate clinically relevant treatment effect of afamelanotide
Patients diagnosed with erythropoietic protoporphyria (EPP) receiving SCENESSE® (afamelanotide) were able to expose skin to direct sunlight without burns and pain and recorded an improved Quality of Life. Melbourne, Australia…
Wednesday, 14 December 2011
Encouraging interim safety results of SCENESSE® in Phase II study in organ transplant recipients (OTRs)
In organ transplant patients who experience a high rate of skin cancers and co-morbidity, no significant safety concerns were seen during first 12 months of consecutive use of SCENESSE®. Melbourne,…
Monday, 12 December 2011
Appendix 3B
Appendix 3B - New issue announcement, application for quotation of additional securities and agreement. For further details see the attached PDF.
Thursday, 17 November 2011
Change of Director's Interest Notice x 4
Four Appendix 4Y (Change of Director's Interest Notice) documents have been lodged with the ASX. For further details see the attached PDF.
Thursday, 17 November 2011
Appendix 3B & Lapse and Forfeit of Unlisted Conditional Performance Rights
Appendix 3B & Lapse and Forfeit of Unlisted Conditional Performance Rights. For further details see the attached PDF.
